Last updated: February 24, 2026
What Is the Drug Associated With the NDC 66758-0147?
The National Drug Code (NDC) 66758-0147 corresponds to Libtayo (cemiplimab-rwlc), a PD-1 inhibitor monoclonal antibody approved by the FDA for various indications including cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, and non-small cell lung cancer (NSCLC). Its approval status and indications place it among targeted immunotherapies used for skin and lung cancers (FDA, 2018).
Market Position and Competition
Therapeutic Area
Libtayo belongs to immune checkpoint inhibitors, competing primarily with pembrolizumab (Keytruda) and nivolumab (Opdivo). Its primary treatment markets include:
- Cutaneous squamous cell carcinoma (CSCC)
- Basal cell carcinoma (approved 2021)
- Non-small cell lung cancer (NSCLC)
Market Size
The global oncology immunotherapy market is valued at approximately USD 66 billion in 2022, with projections reaching USD 123 billion by 2030 (Grand View Research, 2022). PD-1/PD-L1 inhibitors represent a substantial share of this market.
Revenue and Usage Data
In Q4 2022, Libtayo sales in the US totaled approximately USD 200 million, representing a 30% year-over-year growth. Its adoption is driven largely by FDA approvals in additional indications and increasing usage in skin cancers.
Price Benchmarks for Similar Drugs
| Drug |
Indication |
Price per Dose |
Annual Cost |
| Pembrolizumab |
Multiple solid tumors |
USD 13,000 |
USD 156,000 |
| Nivolumab |
Melanoma, lung cancer |
USD 12,500 |
USD 150,000 |
| Libtayo (2023) |
CSCC, BCC, NSCLC |
USD 15,000 |
USD 180,000 |
Note: Prices are approximate wholesale acquisition costs (WAC).
Pricing Trends and Future Projections
Current Pricing Dynamics
Libtayo’s initial pricing was set slightly above competing PD-1 inhibitors, attributed to its newer market entry and targeted indications. As more indications receive approval and biosimilar competition is not imminent, steady price retention is expected.
Price Drivers
- Market expansion: FDA approvals for BCC and NSCLC expand patient access.
- Competitive landscape: Dominance by Keytruda and Opdivo sustains high pricing.
- Reimbursement policies: Payer negotiations influence net prices.
Future Price Trends
| Year |
Estimated Price per Dose |
Rationale |
| 2024 |
USD 15,000 |
Stable due to limited biosimilar competition and high demand. |
| 2025 |
USD 15,000–16,000 |
Slight increases driven by inflation, market expansion. |
| 2026 |
USD 14,500–15,500 |
Potential price compression if biosimilars or generics emerge. |
Sources project a compound annual growth rate (CAGR) of approximately 3% for Libtayo’s price, consistent with the overall immune-oncology segment (IQVIA, 2022).
Market Penetration and Revenue Outlook
Expected market penetration increases as FDA expands indications and dosing recommendations. In the next five years, US sales could reach USD 1.2 billion annually, driven by:
- Growing incidence of skin cancers and NSCLC
- Expanded payer coverage
- Increasing clinical adoption
International markets are emerging, but lack of detailed pricing and approval data limits precise projections. Prices in Europe and Asia are typically 20-30% lower than US benchmarks.
Key Takeaways
- Libtayo (NDC 66758-0147) is a PD-1 inhibitor with FDA approval for skin cancers and NSCLC.
- The US market generated approx. USD 200M in Q4 2022, with steady growth expected.
- Current pricing is around USD 15,000 per dose; annual costs approximate USD 180,000.
- Market competition includes Keytruda and Opdivo, constraining significant price discounts.
- Price projections suggest stable or modestly increasing prices through 2026, with US revenue potential exceeding USD 1 billion annually.
FAQs
1. How does Libtayo’s pricing compare to other PD-1 inhibitors?
Libtayo’s price per dose is slightly higher (~USD 15,000) compared to Keytruda and Opdivo (~USD 12,500–13,000), reflecting its newer indication profile and market positioning.
2. What factors could influence Libtayo’s future pricing?
Introduction of biosimilars, governmental reimbursement policies, evolving clinical guidelines, and competition from other immunotherapies.
3. Are there significant differences in pricing internationally?
Yes, prices in Europe and other regions are generally 20-30% lower, influenced by healthcare systems and pricing negotiations.
4. What is the potential impact of biosimilars or generics?
Biosimilar entrants could reduce prices by 10-20% within 3–5 years, impacting revenue and market share.
5. What is the projected revenue for Libtayo in the next five years?
US revenues could reach USD 1.2 billion annually, driven by increasing indications and market adoption.
References
- FDA. (2018). FDA approves Libtayo for certain advanced or metastatic skin cancers.
- Grand View Research. (2022). Oncology Immunotherapy Market Size, Share & Trends.
- IQVIA. (2022). Pharmaceutical Market Trends.
